Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 2
Submit an article Journal homepage
278
Views
34
CrossRef citations to date
0
Altmetric
Drug Evaluation

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

Raf Crabbé Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Grégoire Vuagniaux Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Jean-Maurice Dumont Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Valérie Nicolas-Métral Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
,
Judith Marfurt Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
&
Laura Novaroli Debiopharm SA, Chemin Messidor 5-7, PO Box 5911, CH-1002 Lausanne, Switzerland +41 21 321 0111; +41 21 321 0169; [email protected]
Pages 211-220 | Published online: 15 Dec 2008

Bibliography

  • Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130(1):231-64
  • Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13(17):2436-41
  • Soriano V, Madejon A, Vispo E, et al. Emerging drugs for hepatitis C. Expert Opin Emerg Drugs 2008;13(1):1-19
  • Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5(9):558-67
  • NIH. National Institute of Health consensus development conference statement: management of hepatitis C. Hepatology 2002;365(Suppl 1):S3-S20
  • Booth J, O'Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl I):i1-21
  • Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42(4):962-73
  • Cross TJ, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgrad Med J 2008;84(990):172-6
  • Houck DR, Hopkins S. Preclinical evaluation of SCY-635, a cyclophilin inhibitor with potent anti-HCV activity. Hepatology 2006;44(Suppl 1):534A
  • Watashi K, Shimotohno K. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy. Rev Med Virol 2007;17(4):245-52
  • Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005;129(3):1031-41
  • Fernandes F, Poole DS, Hoover S, et al. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 2007;46(4):1026-33
  • Yang F, Robotham JM, Nelson HB, et al. Cyclophilin A is an essential cofactor for Hepatitis C virus infection and the principal mediator of cyclosporine. A resistance in vitro. J Virol 2008;82(11):5269-78
  • Robida JM, Nelson HB, Liu Z, et al. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol 2007;81(11):5829-40
  • Bobardt M, Tang H, Sakamoto N, et al. The isomerase activity of cyclophilin A is critical for HCV replication. 15th International Symposium on Hepatitis C Virus & Related Viruses; 2008; San Antonio, Texas
  • Kaul A, Stauffer S, Schmitt J, et al. Role of cyclophilins in hepatitis C virus replication. 15th International Symposium on Hepatitis C Virus & Related Viruses; 2008; San Antonio, Texas
  • Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006;43(4):761-70
  • Gallay P, Flisiak R, Horban A, et al. The reduction of both cyclophilin B and HCV-RNA by the cyclophilin inhibitor Debio 025 confirms the importance of cyclophilin B for HCV replication in man [abstract 787]. J Hepatol 2007;(Suppl 46):S296
  • Coelmont L, Kaptein S, Paeshuyse J, et al. Debio 025, a cyclophilin binding molecule, is highly efficient in 1 clearing HCV replicon 2 containing cells, alone or when combined with STAT-C inhibitors. Antimicrob Agents Chemother 2008; In press
  • Inoue K, Umehara T, Ruegg UT, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology 2007;45(4):921-8
  • Wiedemann B, Puyang X, Poulin D, et al. Characterization of the mechansim of resistance to cyclophilin inhibitors in HCV replicon. 15th International Symposium on Hepatitis C & Related Viruses; 2008; San Antonio, Texas
  • Goto K, Watashi K, Inoue D, et al. The emergence of a cyclophilin inhibitor-resistant HCV variant with a mutation in NS5A. 14th International Symposium on Hepatitis C Virus & Related Viruses; 2007; Glasgow, Scotland
  • Hopkins S, Scorneaux B, Harris R, et al. The genetic and biochemical basis for restistance to SCY-635. 59th Annual Meeting of the American Association for the Study of Liver Diseases; 2008; San Francisco, California
  • Coelmont L, Paeshuyse J, Kaptein S, et al. The cyclophilin inhibitor Debio 025 is a potent inhibitor of hepatitis C virus replication in vitro and has a unique resistance profile. 14th International Symposium on Hepatitis C Virus & Related Viruses; 2007; Glasgow, Scotland
  • Kronke M, Leonard WJ, Depper JM, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984;81(16):5214-18
  • Ptak RG, Gallay PA, Jochmans D, et al. Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother 2008;52(4):1302-17
  • Hansson MJ, Mattiasson G, Mansson R, et al. The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J Bioenerg Biomembr 2004;36(4):407-13
  • Gomez L, Thibault H, Argaud L, et al. Postconditioning and DEBIO-025 prevent LV remodeling and reduce mortality following acute myocadial infarction in mice. World Congress of Cardiology; 2006; Barcelona, Spain
  • Angelin A, Tiepolo T, Sabatelli P, et al. Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Natl Acad Sci USA 2007;104(3):991-6
  • Millay DP, Sargent MA, Osinska H, et al. Genetic and pharmacologic inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. Nat Med 2008;14(4):442-7
  • Reutenauer J, Dorchies OM, Patthey-Vuadens O, et al. Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy. Br J Pharmacol 2008;155(4):574-84
  • Steyn D, Richman DD, Aeschlimann C, et al. A double blind placebo controlled study in HIV-1-infected subjects on the safety, pharmacokinetics and antiviral effect of cyclophilin A targeting DEBIO-025. 13th Conference on Retroviruses and Opportunistic Infections (CROI); 2006; Denver, Colorado
  • Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008;47:817-26
  • Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007;132(4):1270-8
  • Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a Phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;1314:997-1002
  • Fernández I, Castellano G, Domingo MJ, et al. Influence of viral genotype and level of viremia on the severity of liver injury and the response to interferon therapy in Spanish patients with chronic C infection. Scand J Gastroenterol 1997;32(1):70-6
  • Pauli-Magnus C, Stieger B, Meier Y, et al. Enterohepatic transport of bile salts and genetics of cholestasis. J Hepatol 2005;43(2):342-57
  • Kamisako T, Leier I, Cui Y, et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 1999;30(2):485-90
  • Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005;39(1 Suppl):S3-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.